Lv1
30 积分 2025-12-03 加入
Discovery of Daraxonrasib (RMC-6236), a Potent and Orally Bioavailable RAS(ON) Multi-selective, Noncovalent Tri-complex Inhibitor for the Treatment of Patients with Multiple RAS-Addicted Cancers
13小时前
待确认
Amorphous solid dispersions: Utilization and challenges in preclinical drug development within AstraZeneca
8个月前
已完结
皖公网安备34019202002308
